CLEARSIDE BIOMEDICAL INC (CLSD) Stock News

USA - NASDAQ:CLSD - US1850631045 - Common Stock

3.9 USD

+0.1 (+2.63%)

Last: 10/24/2025, 8:16:22 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CLSD Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Benzinga - Mentions: MBRX CNC MOH IBIO ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

a month ago - By: Benzinga - Mentions: SNGX DRIO CRNX ORGO ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

2 months ago - By: Clearside Biomedical, Inc.

Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress

3 months ago - By: Zacks Investment Research - Mentions: ARCT

Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates

3 months ago - By: Zacks Investment Research - Mentions: CGEN

Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates

3 months ago - By: Clearside Biomedical, Inc.

Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

3 months ago - By: Clearside Biomedical, Inc.

Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline

4 months ago - By: Clearside Biomedical, Inc.

Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting

5 months ago - By: Zacks Investment Research

Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know

5 months ago - By: Clearside Biomedical, Inc.

Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum

5 months ago - By: Zacks Investment Research - Mentions: VTGN

Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates